Revenue from anti-CD20 therapeutic programs — Total Revenue
Biogen Revenue from anti-CD20 therapeutic programs — Total Revenue decreased by 15.1% to $419.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.8%, from $378.20M to $419.10M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or expanded clinical utility of the company's anti-CD20 therapies, while a decrease suggests competitive pressure or declining demand for these specific treatments.
Detailed definition
This metric represents the total gross revenue generated from the company's portfolio of anti-CD20 therapeutic programs....
Peer comparison
Comparable to oncology or immunology segment revenues reported by other large-cap biopharmaceutical companies with monoclonal antibody portfolios.
biib_segment_revenue_from_anti_cd20_therapeutic_programs_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $440.00M | $415.40M | $414.10M | $399.40M | $436.30M | $416.90M | $447.90M | $399.50M | $433.40M | $420.90M | $394.00M | $444.50M | $446.20M | $378.20M | $467.30M | $493.90M | $419.10M |
| QoQ Change | — | -5.6% | -0.3% | -3.5% | +9.2% | -4.4% | +7.4% | -10.8% | +8.5% | -2.9% | -6.4% | +12.8% | +0.4% | -15.2% | +23.6% | +5.7% | -15.1% |
| YoY Change | — | — | — | — | -0.8% | +0.4% | +8.2% | +0.0% | -0.7% | +1.0% | -1.4% | +2.6% | +6.0% | -4.0% | +5.1% | +10.7% | +10.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's revenue from anti-cd20 therapeutic programs — total revenue?
- Biogen (BIIB) reported revenue from anti-cd20 therapeutic programs — total revenue of $419.10M in Q1 2026.
- How has Biogen's revenue from anti-cd20 therapeutic programs — total revenue changed year-over-year?
- Biogen's revenue from anti-cd20 therapeutic programs — total revenue increased by 10.8% year-over-year, from $378.20M to $419.10M.
- What does revenue from anti-cd20 therapeutic programs — total revenue mean?
- The total sales revenue generated by the company's anti-CD20 therapeutic product line.